Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Department of Radiology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Neurol Sci. 2024 Feb;45(2):663-670. doi: 10.1007/s10072-023-06995-3. Epub 2023 Sep 12.
Understanding the benefits and risks of endovascular therapy (EVT) is crucial for elderly patients with large ischemic cores, as the combination of advanced age and extensive brain infarction may negatively impact clinical outcomes.
The study retrospectively analyzed clinical outcomes for elderly stroke patients (age ≥ 70) with large ischemic cores (Alberta Stroke Program Early CT Score [ASPECTS] < 6 or ischemic cores ≥ 70 ml) in the anterior circulation using data from our prospective database between June 2018 and January 2022. The effectiveness and risks of EVT in those patients were investigated, with the primary outcome being fair outcome (modified Rankin Scale, mRS ≤ 3).
Among 182 elderly patients with large ischemic core volume (120 in the EVT group and 62 in the non-EVT group), 20.9% (38/182, 22.5% in the EVT group vs. 17.7% in the non-EVT group) achieved a fair outcome. Meanwhile, 49.5% (90/182, 45.8% in the EVT group vs. 56.5% in the non-EVT group) of them died at 3 months. The benefits of EVT numerically exceeded non-EVT treatment for those aged ≤ ~ 85 years or with a mismatch volume ≥ ~ 50 ml. However, after adjustment, EVT was associated with an increased risk of symptomatic intracranial hemorrhage (aOR 4.24, 95%CI 1.262-14.247).
This study highlights the clinical challenges faced by elderly patients with large infarctions, resulting in poor outcomes at 3 months. EVT may still provide some benefits in this population, but it also carries an increased risk of intracranial hemorrhage.
对于存在大缺血核心的老年患者,了解血管内治疗(EVT)的获益和风险至关重要,因为高龄和广泛脑梗死的结合可能对临床结局产生负面影响。
本研究回顾性分析了 2018 年 6 月至 2022 年 1 月期间前瞻性数据库中年龄≥70 岁、前循环存在大缺血核心(Alberta 卒中项目早期 CT 评分[ASPECTS]<6 或缺血核心≥70ml)的老年卒中患者的临床结局。评估了这些患者 EVT 的有效性和风险,主要结局为良好结局(改良 Rankin 量表,mRS≤3)。
在 182 例大缺血核心体积的老年患者中(EVT 组 120 例,非 EVT 组 62 例),20.9%(38/182,EVT 组 22.5%,非 EVT 组 17.7%)达到良好结局。同时,90%(90/182,EVT 组 45.8%,非 EVT 组 56.5%)的患者在 3 个月时死亡。对于年龄≤85 岁或不匹配体积≥50ml 的患者,EVT 的获益在数值上超过了非 EVT 治疗。然而,经过调整后,EVT 与症状性颅内出血风险增加相关(OR 4.24,95%CI 1.262-14.247)。
本研究强调了存在大梗死的老年患者所面临的临床挑战,导致 3 个月时结局较差。EVT 可能仍为该人群带来一定获益,但也增加了颅内出血的风险。